1. Pharmacogenetics of warfarin dosing
Pharmacogenetics of warfarin dosing. Warfarin is metabolized by CYP2C9 to inactive metabolites and exerts its anticoagulant effect partly via inhibition of VKORC1, an enzyme necessary for reduction of inactive to active vitamin K. Common polymorphisms in both genes, CYP2C9 and VKORC1, have an effect on warfarin pharmacokinetics and pharmacodynamics, respectively, to affect the population mean therapeutic doses of warfarin necessary to maintain the desired degree of anticoagulation (often measured by the INR blood test) and minimize the risk of too little anticoagulation (thrombosis) or too much anticoagulation (bleeding). See also Figure 32–6 and Table 32–2. (Data from Caraco et al., 2008; Schwarz et al., 2008; Wen et al., 2008.)
Source: Pharmacogenetics, Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e
Citation: Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e; 2017 Available at: Accessed: October 08, 2017
Copyright © 2017 McGraw-Hill Education. All rights reserved